Gritstone raises $75M in follow-on as second neoantigen immunotherapy heads to clinic

Days after saying it plans to accelerate its second neoantigen immunotherapy into the clinic, Gritstone has raised $74.8 million in a follow-on.

Gritstone Oncology Inc. (NASDAQ:GRTS) sold $6.5 million

Read the full 283 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE